<?xml version='1.0' encoding='utf-8'?>
<section xmlns:codified="https://code.dccouncil.us/schemas/codified" xmlns:codify="https://code.dccouncil.us/schemas/codify" xmlns:xi="http://www.w3.org/2001/XInclude" containing-doc="D.C. Code">
  <num>44-109.02</num>
  <heading>Pre-admission medication management assessment.</heading>
  <text>Within 30 days prior to admission, the ALR shall consult with the prospective resident’s healthcare practitioner regarding:</text>
  <para>
    <num>(1)</num>
    <text>The prospective resident’s current medication profile, including a review  of nonprescription drugs;</text>
  </para>
  <para>
    <num>(2)</num>
    <text>Possible adverse interactions;</text>
  </para>
  <para>
    <num>(3)</num>
    <text>Common expected or unexpected side effects; and</text>
  </para>
  <para>
    <num>(4)</num>
    <text>The potential that such medications have to act as chemical restraints.</text>
  </para>
  <annotations>
    <annotation doc="D.C. Law 13-127" type="History">June 24, 2000, D.C. Law 13-127, § 902, 47 DCR 2647</annotation>
  </annotations>
</section>
